BioStock: CombiGene’s scientific founders on the agreement with Spark

Recently, gene therapy company CombiGene signed an exclusive global license agreement for their gene therapy candidate CG01 with Spark Therapeutics. The deal is potentially worth $328.5 million excluding royalties. Much has happened since CombiGene was formed and BioStock turned to the scientific founders Professor Merab Kokaia and Associate Professor David Woldbye, for a comment on the company’s development.

Read the full interview with Merab Kokaia and David Woldbye at biostock.se:

https://www.biostock.se/en/2021/10/combigenes-scientific-founders-on-the-agreement-with-spark/

This is a pressrelease from BioStock - Connecting Innovation & Capital. https://www.biostock.se/